January 24, 2017 8:18 AM ET

Biotechnology

Company Overview of Genocea Biosciences, Inc.

Company Overview

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design vaccines and immunotherapies that act through T cell immune responses. Its lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections. It is also developing GEN-001, a product candidate that is in pre-clinical stage for treating chlamydia prophylaxis; GEN-002, which is in pre-clinical stage for the treatment of genital herpes prophylaxis; and GEN-005 that is in research st...

100 Acorn Park Drive

5th Floor

Cambridge, MA 02140

United States

Founded in 2006

87 Employees

Phone:

617-876-8191

Fax:

617-876-8192

Key Executives for Genocea Biosciences, Inc.

Chief Executive Officer, President and Director
Age: 47
Total Annual Compensation: $427.4K
Chief Financial Officer and Secretary
Age: 41
Total Annual Compensation: $328.0K
Chief Medical Officer
Age: 64
Total Annual Compensation: $378.7K
Compensation as of Fiscal Year 2015.

Genocea Biosciences, Inc. Key Developments

Genocea Biosciences, Inc. - Special Call

To discuss Positive GEN-003 Phase 2b 6-Month

Genocea Biosciences, Inc. - Special Call

To discuss positive GEN-003 phase 2b six month results

Genocea Biosciences, Inc. Announces Positive Clinical Results from Planned Interim Analysis of Ongoing Placebo-Controlled Phase 2b Trial Evaluating Gen-003 for the Treatment of Genital Herpes Infections

Genocea Biosciences, Inc. announced positive clinical results from a planned interim analysis of its ongoing placebo-controlled Phase 2b trial evaluating GEN-003 for the treatment of genital herpes infections. Even in a trial this small, at six months after dosing, GEN-003 demonstrated statistically significant improvements versus placebo across multiple clinical endpoints. The 60 µg per antigen /50 µg of adjuvant dose of GEN-003 significantly reduced the rate of genital lesions during the six months following dosing compared to placebo (4.5% of days vs. 7.9%, respectively; 41% reduction vs. placebo, p<0.05). The genital lesion rate is an important overall measure of disease that captures both the frequency and duration of recurrences, both of which are important to both patients and their caregivers. In the trial, GEN-003 also consistently demonstrated significant benefits versus placebo across several other clinical endpoints across the dose groups. In aggregate, the data from the GEN-003 Phase 2 clinical trials continue to support the selection of the 60 µg per antigen /50 µg of adjuvant dose for the planned Phase 3 program. GEN-003 also continues to demonstrate a safety profile appropriate for its therapeutic setting in the judgment of the trial’s independent Drug Monitoring Committee.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Genocea Biosciences, Inc., please visit www.genocea.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.